Kaken Pharmaceutical Co., Ltd. (KAKEN) is a specialty pharmaceutical company in Japan with strong experience in developing and commercializing novel pharmaceuticals and medical devices in the fields of orthopedics, dermatology and surgery.
The origins of KAKEN can be traced back to the Institute of Physical and Chemical Research (Riken), which was established in 1917. In 1948, Riken reorganized into Kagaku-Kenkyusho, which is the precursor of KAKEN, and started its pharmaceutical business by developing a new way to manufacture penicillin utilizing Riken’ proprietary technologies.
KAKEN has since broadened the scope of its business activities to include the production and marketing of pharmaceuticals such as streptomycin, an anti-tuberculosis drug, and various antifungal agents. In recent years, KAKEN concentrates its R&D resources in inflammation/immunology (dermatitis, rheumatoid arthritis and osteoarthritis), pain relief and fungal infection areas.
KAKEN's ongoing quest is to bring smiles and happiness to as many people as possible. For this purpose, KAKEN strives to improve the quality of life of patients through the development and distribution of superior pharmaceuticals.
(As of March 31, 2017)
|Company Name||KAKEN PHARMACEUTICAL CO., LTD.|
|Representative||Tetsuo Onuma, President and Representative Director|
|Incorporated||March 1, 1948|
|Shareholders||10,660 (unit amount shares: 9,422)|
|Paid-in Capital||23,853 million yen|
|Listing||Tokyo Stock Exchange First Section|
|Stock Code Number||4521|
|Business||Production and marketing of pharmaceuticals
including medical devices and agrochemicals
Rental of real estate holdings